Stimuli-Responsive Nanocarriers in Oncology: Tumor Microenvironment Triggers, Overcoming Biological Barriers, and Clinical Reality
Abstract
Conventional anticancer nano-therapies often rely on passive accumulation through the enhanced permeability and retention (EPR) effect, resulting in insufficient penetration of tumor tissue and heterogeneous cellular uptake. Smart nanocarriers that are able to respond to specific stimuli through conformational, charge-reversal, or structural phase changes to improve targeting efficacy at the tumor site have been proposed as promising alternatives. These stimuli-responsive smart nanocarriers undergo conformational changes or transitions in charge, solubility, or structure when exposed to a specific triggering stimulus. Smart nanocarriers can be triggered by either endogenous biochemical perturbations associated with the tumor microenvironment or external ex vivo physical triggers. The former includes the extracellular and endosomal pH gradients, the increased intracellular glutathione redox potential, and dysregulated proteolytic enzymes in the tumor microenvironment, while the latter includes near-infrared light, alternating magnetic fields, and high-intensity focused ultrasound. This article reviews the fundamental bio responsive molecular mechanisms, nanocarrier types, clinical reality, translational barriers, and design-by-quality principles relevant to the development of responsive nanotherapeutics for clinical oncology.
Keywords: Stimuli-Responsive Nanocarriers, Tumor Microenvironment, Smart Drug Delivery, Redox Trigger, Endosomal Escape, Clinical Translation.
Keywords:
Stimuli-Responsive Nanocarriers, Tumor Microenvironment, Smart Drug Delivery, Redox Trigger, Endosomal Escape, Clinical TranslationDOI
https://doi.org/10.22270/jddt.v16i10.8035References
1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760. https://doi.org/10.1038/nnano.2007.387 PMid:18654426
2. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2): 101-124. https://doi.org/10.1038/s41573-020-0090-8 PMid:33277608
3. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-664. https://doi.org/10.1038/nrclinonc.2010.139 PMid:20838415 PMCid:PMC3065247
4. Sun Q, Zhou Z, Qiu N, Shen Y. Rational design of cancer nanomedicine: Overcoming the challenges of the tumor microenvironment. Adv Mater. 2017;29(14):1606628. https://doi.org/10.1002/adma.201606628 PMid:28234430
5. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467-1475. https://doi.org/10.1016/j.ymthe.2017.03.013 PMid:28412170 PMCid:PMC5498813
6. Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive nanocarriers for targeted drug delivery. Biomaterials. 2016;85:152-167. https://doi.org/10.1016/j.biomaterials.2016.01.061 PMid:26871891
7. Cheng R, Feng F, Meng F, Deng C, Feijen J, Zhong Z. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release. 2011;152(1):2-12. https://doi.org/10.1016/j.jconrel.2011.01.030 PMid:21295087
8. de la Rica R, Aili D, Stevens MM. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev. 2012;64(11):967-978. https://doi.org/10.1016/j.addr.2012.01.002 PMid:22266127
9. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. https://doi.org/10.1038/s41578-021-00358-0 PMid:34394960
10. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed. 2003;42(38):4640-4643. https://doi.org/10.1002/anie.200250653 PMid:14533151
11. Phillips DJ, Gibson MI. Degradable materials via thiol-disulfide exchange. Biomacromolecules. 2015;16(10):3236-3244.
12. Zhu L, Wang T, Pun SH, Torchilin VP. Multifunctional tumor-targeting polymeric micelles with enzyme-triggered core disassembly. ACS Nano. 2013;7(8):6825-6838.
13. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991-1003. https://doi.org/10.1038/nmat3776 PMid:24150417
14. Shanmugam V, Selvakumar S, Yeh CS. Near-infrared light-responsive nanomaterials in cancer therapy. Chem Soc Rev. 2014;43(17):6254-6287. https://doi.org/10.1039/C4CS00011K PMid:24811160
15. Jordan A, Scholz R, Maier-Hauff K, Johannsen M, Gneveckow U, Thiesen B, et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. J Magn Magn Mater. 2006;225(1-2):118-126. https://doi.org/10.1016/S0304-8853(00)01239-7
16. Sirsi SR, Borden MA. State-of-the-art materials for ultrasound-triggered drug delivery. Adv Healthc Mater. 2014;3(8):1243-1254. https://doi.org/10.1016/j.addr.2013.12.010 PMid:24389162 PMCid:PMC4041842
17. Fleige E, Quadir MA, Haag R. Stimuli-responsive polymers as smart drug delivery systems. Adv Drug Deliv Rev. 2012;64(9):866-884. https://doi.org/10.1016/j.addr.2012.01.020 PMid:22349241
18. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37. https://doi.org/10.1038/nrc.2016.108 PMid:27834398
19. Poon PC, Borys N. Lyso-thermosensitive liposomal doxorubicin: A novel approach to enhance drug delivery. Future Oncol. 2009;5(6):757-765.
20. Singer JW, Baker B, De Vries P, Kumar A, Shaffer S, Vawter E, et al. Poly-(L-glutamic acid)-paclitaxel (CT-2103) in patients with solid tumors: A Phase I and pharmacokinetic study. Ann Oncol. 2003;14(11):1663-1670.
21. Burns KE, Robinson MK, Thévenin D. Acid-sensitive membrane insertion peptides (pHLIPs) for targeted cancer therapeutics. Trends Biotechnol. 2015;33(10):551-562.
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Dipu Pan, Shubhajit Sarkar , Souvik Adhikary , Amit Mia , Shamim Khandokar , Kunal Das , Bipasha De , Megha Das , Sagarika Ghosh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.